Carrying a celiac gene: how often it leads to celiac disease and what changes the odds

Short answer

Most people who carry the celiac-linked gene variants do not develop celiac disease: NIDDK says about 30 percent of people have DQ2 or DQ8, and only about 3 percent of them develop it3. Figures are higher in some groups: 28.28% of people with two copies of DQ2.5, or DQ2.2 with DQ2.5, were EMA-positive in one US sample of people described as at risk for celiac disease7, 8, and the pooled prevalence in first-degree relatives of patients was 7.5% in one meta-analysis14. The ACG guideline says the frequency is substantially increased in such relatives51.

Published by Gluten Verdict · updated · 14 sources, each linked below

Reviewed by Mark Peter, Registered dietitian (RD), on

Grandmother and adult daughter peeling potatoes at a kitchen sink, seen from behind

Key points

  • NIDDK: about 30 percent of people have DQ2 or DQ8, and only about 3 percent of them develop celiac disease3.
  • In one US sample of people described as at risk, 28.28% of people with two copies of DQ2.5 (or DQ2.2 with DQ2.5) were EMA-positive, against 0.16% of people with neither DQ2 nor DQ87, 8, 10.
  • One 2015 meta-analysis pooled a celiac disease prevalence of 7.5% in first-degree relatives of patients and 2.3% in second-degree relatives14.
  • Two randomized trials in infants with a relative did not find that the timing of gluten introduction changed the risk of celiac disease; in one, later introduction was associated with a delayed onset23, 26.
  • The 2023 ACG guideline lists the optimal serologic screening interval for people at increased risk as a question for future research40.

Common gene, uncommon disease: whose figures these are

Celiac disease almost always occurs in people who carry one of two groups of gene variants, DQ2 and DQ8, and people without them are very unlikely to develop it1. Coeliac UK, writing for clinicians, states the same fact the other way round: 99.6% of patients with coeliac disease carry DQ2.5, DQ8 or DQ2.22.

Four figures, four different counts
FigureWhose figure, and what it counts
About 30 percent of people have DQ2 or DQ8NIDDK: carriers of either variant among people in general3.
Only about 3 percent of people with DQ2 or DQ8 develop celiac diseaseNIDDK: the share of carriers who develop the disease3.
DQ2 and DQ8 haplotypes are found in up to 40% of the general populationCoeliac UK, for clinicians: carriers in the general population, set against a UK prevalence of coeliac disease of 1%4.
About 1 percent of people around the world have celiac diseaseNIDDK estimate; it adds that about 2 million people in the United States have the disease5.

The two sources do not give the same carrier share (about 30 percent and up to 40%), so this page quotes each and does not merge them or work out a combined figure. What both say is that carriers are a much larger group than people with the disease3, 4. Coeliac UK concludes that other factors must work with the HLA types to cause the condition4.

A gene result is not a diagnosis. NIDDK says having DQ2 or DQ8 alone does not mean you have celiac disease, and that most people with these gene variants do not develop it6.

Risk by genotype: one copy, two copies, DQ8

One large US study sorted 10,191 people described as at risk for celiac disease by their HLA-DQ type and counted who tested positive for anti-endomysial IgA antibodies (EMA)7. The study identified people with celiac disease by this blood test7. Because the sample was described as at risk rather than drawn from the general population, read the table as a comparison between groups, not as a population rate.

EMA-positive share by HLA-DQ group (Pietzak 2009)
HLA-DQ groupEMA-positive within the group
Two copies of DQ2.5, or DQ2.2 together with DQ2.528.28% (95% CI 24.55-32.26)8
DQ2.2/DQ8 or DQ2.5/DQ811.78% (95% CI 9.13-14.87)10
DQ2.5 heterozygous (one copy)9.09% (95% CI 7.82-10.51)9
DQ8 homozygous (two copies)8.42% (95% CI 3.71-15.92)9
DQ8 heterozygous (one copy)2.11% (95% CI 1.43-3.00)9
Neither DQ2 nor DQ80.16% (95% CI 0.07-0.34)10

The two-copy DQ2.5 group made up 5.38% of the samples and had the highest EMA-positive rate in the table8, 9, 10. The group with neither variant made up 42.03% of the samples (4283 of them), and 0.16% of those were EMA-positive10.

Children followed from birth

The TEDDY study followed 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8 from birth in the United States, Finland, Germany and Sweden. It counted celiac disease autoimmunity as tTG antibodies on two consecutive tests at least 3 months apart, and celiac disease as a biopsy diagnosis or persistently high tTG antibodies11.

By age 5, the risks of autoimmunity and of celiac disease were 11% and 3% among children with a single DR3-DQ2 haplotype, and 26% and 11% among those with two copies12. The study also reported a higher risk in Sweden than in the other countries, and says this highlights the importance of studying environmental factors13.

The outcomes (EMA positivity, persistent tTG antibodies, a biopsy), the ages and the people studied differ between these two studies, so their numbers describe different things and should not be set side by side as one scale.

How a first-degree relative changes the starting point

The ACG guideline says the frequency of celiac disease is substantially increased in patients who have a first-degree family member affected with it51. In a 2015 meta-analysis, the pooled prevalence of celiac disease was 7.5% in 10,252 first-degree relatives of patients, and 2.3% in 642 second-degree relatives14.

Pooled prevalence of celiac disease by relationship to the patient (Singh 2015)
Relationship to the patientPooled prevalence
Siblings8.9%14
Children (offspring)7.9%14
Parents3.0%14
All first-degree relatives7.5%14
Second-degree relatives2.3%14

The same authors report that the figure also varies by gender and by geographic location15. A 2024 meta-analysis of 34 studies of 10,016 first-degree relatives pooled an 11% seroprevalence and a 7% biopsy-confirmed prevalence16.

The ACG guideline gives a wider range. One large multicenter US study showed a rate as low as 5% in both first-degree and second-degree relatives18, while community-based studies showed up to 20% in siblings and 10% in other first-degree relatives19. It also says the risk is highest in monozygous twins, next HLA-matched siblings, siblings, and then parents and children20.

Infants with a relative, followed for years

Two randomized trials followed infants who had a first-degree relative with celiac disease. PreventCD involved 944 children who were positive for HLA-DQ2 or HLA-DQ821; the cumulative incidence of celiac disease by age 3 was 5.2%22. CELIPREV assigned 832 newborns24; at 10 years, celiac disease autoimmunity was 38% in children with high-risk HLA and 19% in those with standard-risk HLA, and overt celiac disease 26% and 16%25.

These are group figures from trials, not predictions for any one person, and each study counts a different outcome at a different age.

What is established, and what the trials did not show

NIDDK says research suggests that celiac disease only occurs in people who have certain genes and eat food that contains gluten27. It adds that not all people who have DQ2 or DQ8 and eat gluten develop the disease28.

The amount of gluten in early childhood

NIDDK says research suggests that among children with a genetic predisposition, those who eat more gluten in early childhood may have a greater risk29. The source study, TEDDY, found that higher gluten intake during the first 5 years of life was associated with increased risk of celiac disease autoimmunity and celiac disease among genetically predisposed children30. Its abstract describes TEDDY as a prospective observational birth cohort study31, which is why the finding is worded as an association.

The age at which gluten is first given

Two randomized trials tested the age at which gluten is first given to infants who had a relative with celiac disease21, 24. In PreventCD, small quantities of gluten at 16 to 24 weeks of age did not reduce the risk of celiac disease by 3 years of age in this high-risk group23. In CELIPREV, neither delayed introduction of gluten nor breast-feeding modified the risk among at-risk infants, although later introduction of gluten was associated with a delayed onset of disease26.

Still a hypothesis: infections, microbes and other genes

NIDDK lists two ideas among the other factors under study. Research suggests that a higher number of infections in early life and certain digestive tract infections may increase the risk32, and experts also think changes in the microbiome could play a role33.

A 2019 review says several cohort studies have shown that different gastrointestinal infections increase risk, but that the mechanisms by which microbes take part have remained elusive34. It treats the idea that infections can break tolerance to gluten in genetically susceptible people as a hypothesis35.

On other genes, NIDDK says researchers are studying genes that may raise the chance of celiac disease in people who have DQ2 or DQ836, and Coeliac UK says no firm conclusions have been made about their importance37.

Can a carrier develop celiac disease later?

The 2023 ACG guideline treats how often a person at increased risk converts later in life as an open question. It lists “What is the rate of seroconversion across the life course for individuals at increased risk of developing CD, and what is the optimal serologic screening interval?” under future research40.

NIDDK says celiac disease affects children and adults38. In the TEDDY gluten analysis, the incidence of both outcomes peaked at the age of 2 to 3 years39; that describes a birth cohort31.

A negative gene result is a different matter from a negative blood test. Coeliac UK says that, although never a guarantee, being HLA-negative would be very reassuring41. The ACG guideline says HLA testing is not required for diagnosis in all cases but may be helpful in selected situations42, and that if it is negative, celiac disease is ruled out43.

What NIDDK, the ACG and Coeliac UK say about testing

This is what the sources report. Whether and when to test is a decision for a person and their doctor.

  • NIDDK: doctors in the United States do not routinely screen people for celiac disease, but blood relatives of people with celiac disease, and people with type 1 diabetes, should talk with their doctor about their chances of getting the disease and whether they should be tested44.
  • The 2023 ACG guideline: patients with a first-degree family member who has a confirmed diagnosis of celiac disease should be tested whether they show possible signs or symptoms or laboratory evidence of it45, and testing of asymptomatic relatives should be considered46.
  • Coeliac UK, for clinicians: HLA DQ2 and 8 typing is suggested in guidance as helpful in excluding patients from future testing in at-risk groups, first-degree relatives among them47. In its worked scenarios, a positive result “does not diagnose them as having coeliac disease”, and for a patient with suspected coeliac disease who is not responding to a gluten-free diet it is “actually not very helpful”, as so many of the general population are DQ positive48.
  • The 2020 ESPGHAN guideline on diagnosing coeliac disease in children: for the no-biopsy diagnosis, which may be applied when TGA-IgA is at least 10 times the upper limit of normal and EMA-IgA tests positive in a second blood sample, HLA DQ2/DQ8 determination is not an obligatory criterion49.

On how often a person at increased risk should repeat testing, NIDDK’s diagnosis page gives no interval50, and the ACG guideline lists the optimal serologic screening interval as a question for future research40.

Questions people ask

Does having the celiac gene mean I will get celiac disease?

No. NIDDK says about 30 percent of people have DQ2 or DQ8 and only about 3 percent of them develop celiac disease3. It also says not all people who have the variants and eat gluten develop the disease28.

What percent of people with the celiac gene get celiac disease?

NIDDK’s figure is about 3 percent of people with DQ2 or DQ83. Studies of selected groups report higher numbers: in one US sample of people described as at risk, 28.28% of people with two copies of DQ2.5 (or DQ2.2 with DQ2.5) were EMA-positive7, 8, and in TEDDY, 11% of children with two copies of DR3-DQ2 had celiac disease by age 512.

Is the risk the same for every relative?

No. In the 2015 meta-analysis the pooled prevalence was 8.9% in siblings, 7.9% in offspring and 3.0% in parents of patients14.

Can someone have celiac disease and no symptoms?

Yes. In a 2024 meta-analysis of first-degree relatives, 34% of those with celiac disease were asymptomatic17.

Does a negative gene test rule out celiac disease?

NIDDK says people without DQ2 or DQ8 are very unlikely to develop celiac disease1. Coeliac UK says that, although never a guarantee, being negative would be very reassuring41, and the ACG guideline says that if HLA testing is negative, celiac disease is ruled out43.

More in Celiac genetics and family risk

Sources